Definium Therapeutics, Inc.

The decrease was primarily due to increases in operating expenses of $16.4 million, changes in the fair value of warrants issued in our September 2022 underwritten offering of $15.6 million, the absence of a $2.5 million gain on extinguishment of contribution payable from 2024 and increased interest expense related primarily to the amendment of our credit facility of $1.8 million.

SEC original ↗Definium Therapeutics, Inc. — Earnings release (8-K exhibit)EX-99Jul 31, 2025

Through June 30, 2026, the Company s financial support has primarily been provided by proceeds from the issuance of its common shares, no par value per share ( Common Shares ), and warrants to purchase Common Shares, and the Company s credit facility.

SEC original ↗Definium Therapeutics, Inc. — 10-Q Quarterly report10-QAug 6, 2026

Dividend and interest income are recognized when earned.

SEC original ↗Definium Therapeutics, Inc. — 10-Q Quarterly report10-QAug 6, 2026

The Company reviews its portfolio of available-for-sale debt securities, using both quantitative and qualitative factors, to determine if declines in fair value below cost have resulted from a credit-related loss or other factors.

SEC original ↗Definium Therapeutics, Inc. — 10-Q Quarterly report10-QAug 6, 2026

CREDIT FACILITY On August 11, 2023, the Company and certain of its subsidiaries party thereto, as co-borrowers (together with the Company, the Borrowers ) entered into a Loan and Security Agreement (the Loan Agreement ) with K2 HealthVentures LLC ( K2HV ), as administrative agent and Canadian collateral agent for lenders thereunder (K2HV, together with any other lender from time to time, the "Lenders"), and Ankura Trust Company, LLC, as collateral trustee for the Lenders , providing for an aggregate principal amount of term loans of up to $ 50.0 million (the Term Loans ).

SEC original ↗Definium Therapeutics, Inc. — 10-Q Quarterly report10-QAug 6, 2026

Other than as described above, the proceeds of borrowings under the Amended Loan Agreement are expected to be used for working capital and other general corporate purposes and/or to further support commercial activities and/or business development opportunities.

SEC original ↗Definium Therapeutics, Inc. — 10-Q Quarterly report10-QAug 6, 2026

In parallel, we are advancing our commercial strategy and have continued to strengthen our leadership team with the appointment of Brandi Roberts as Chief Financial Officer.

SEC original ↗Definium Therapeutics, Inc. — Earnings release (8-K exhibit)EX-99Jul 31, 2025

With our clearly defined regulatory strategy, disciplined operational execution, and strong balance sheet, we are well-positioned to advance MM120 ODT as a potential best-in-class therapeutic option for the treatment of GAD and MDD.

SEC original ↗Definium Therapeutics, Inc. — Earnings release (8-K exhibit)EX-99Jul 31, 2025

As a member of the executive team, she leads all aspects of the Company’s financial strategy, capital planning, accounting, investor relations and information technology.

SEC original ↗Definium Therapeutics, Inc. — Earnings release (8-K exhibit)EX-99Jul 31, 2025

While the Company is focused on programs using psychedelic or hallucinogenic compounds and non-hallucinogenic derivatives of these compounds, including in its MM120, MM402 and other product candidates, the Company does not have any direct or indirect involvement with the illegal selling, production or distribution of any substances in the jurisdictions in which it operates.

SEC original ↗Definium Therapeutics, Inc. — Presentation / slide deck (8-K exhibit)EX-99Jul 31, 2025

GAD: generalized anxiety disorder; NDA: new drug application Commercial Framework MM120 ODT LSD D-tartrate Large, Identified, Accessible Opportunity for MM120 ODT High Unmet Need Paradigm Shifting Clinical Profile Efficient Go To Market Strategy Significant Limitations of Existing Treatments MM120 ODT: Potential Best-In-Class Therapy Existing Referral an Administration Infrastructure Sustained clinical response from a single administration10 Identifiable HCPs and patients suffering from the burden of inadequate treatment Poor efficacy, tolerability, and persistence ~50% Discontinue SSRIs in first 4 mos.

SEC original ↗Definium Therapeutics, Inc. — Presentation / slide deck (8-K exhibit)EX-99Jul 31, 2025

Forward-looking information is not based on historical facts, but rather on current expectations and projections about future events and are therefore subject to risks and uncertainties which could cause actual results to differ materially from the future results expressed or implied by the forward-looking statements.

SEC original ↗Definium Therapeutics, Inc. — Earnings release (8-K exhibit)EX-99Jul 31, 2025

There are numerous risks and uncertainties that could cause actual results and the Company's plans and objectives to differ materially from those expressed in the forward-looking information, including history of negative cash flows; limited operating history; incurrence of future losses; availability of additional capital; compliance with laws and regulations; legislative and regulatory developments, including decisions by the Drug Enforcement Administration and states to reschedule any of our product candidates, if approved, containing Schedule I controlled substances, before they may be legally marketed in the U.

SEC original ↗Definium Therapeutics, Inc. — Earnings release (8-K exhibit)EX-99Jul 31, 2025

Forward-looking statements are not based on historical facts, but rather on current expectations and projections about future events and are therefore subject to risks and uncertainties which could cause actual results to differ materially from the future results expressed or implied by the forward-looking statements.

SEC original ↗Definium Therapeutics, Inc. — Presentation / slide deck (8-K exhibit)EX-99Jul 31, 2025

Legal Proceedings 31 Item 1A.

SEC original ↗Definium Therapeutics, Inc. — 10-Q Quarterly report10-QAug 6, 2026

Exhibits 33 Signatures 34 SPECIAL NOTE REGARDING FORWARD-LOOKING STATEMENTS This Quarterly Report on Form 10-Q ("Quarterly Report") contains forward-looking statements about us and our industry that involve substantial risks and uncertainties.

SEC original ↗Definium Therapeutics, Inc. — 10-Q Quarterly report10-QAug 6, 2026

The outcome of the events described in these forward-looking statements is subject to risks, uncertainties and other factors described in the section titled Risk Factors previously disclosed in Part I, Item 1A.

SEC original ↗Definium Therapeutics, Inc. — 10-Q Quarterly report10-QAug 6, 2026